Innate Pharma SA announces today that IPH 1101 in combination with rituximab was authorized to enter the second part of the Phase I/II trial in follicular non-Hodgkin's lymphoma.
| PR in english | 99.65 KB |
| CP en français | 79.24 KB |
Innate Pharma SA announces today that IPH 1101 in combination with rituximab was authorized to enter the second part of the Phase I/II trial in follicular non-Hodgkin's lymphoma.
| PR in english | 99.65 KB |
| CP en français | 79.24 KB |